Marlene Rabinovitch

List of Publications by Year
in descending order

141 papers	17,122 citations	20817 60 h-index	14759 127 g-index
156 all docs	156 docs citations	156 times ranked	16321 citing authors

#	Article	IF	Citations
1	Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunology, 2011, 12, 222-230.	14.5	2,447
2	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	6.7	776
3	Subversion of Cellular Autophagosomal Machinery by RNA Viruses. PLoS Biology, 2005, 3, e156.	5.6	717
4	Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 165-175.	4.5	708
5	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
6	Molecular pathogenesis of pulmonary arterial hypertension. Journal of Clinical Investigation, 2012, 122, 4306-4313.	8.2	552
7	Molecular pathogenesis of pulmonary arterial hypertension. Journal of Clinical Investigation, 2008, 118, 2372-2379.	8.2	548
8	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	2.8	465
9	Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nature Medicine, 2000, 6, 698-702.	30.7	355
10	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	8.2	354
11	Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferatorâ€“Activated Receptor-Î³ Activation. Circulation, 2007, 115, 1275-1284.	1.6	344
12	Regulation of Tenascin-C, a Vascular Smooth Muscle Cell Survival Factor that Interacts with the Î±vÎ²3 Integrin to Promote Epidermal Growth Factor Receptor Phosphorylation and Growth. Journal of Cell Biology, 1997, 139, 279-293.	5.2	335
13	An antiproliferative BMP-2/PPARÎ³/apoE axis in human and murine SMCs and its role in pulmonary hypertension. Journal of Clinical Investigation, 2008, 118, 1846-1857.	8.2	314
14	Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. Journal of Clinical Investigation, 2000, 105, 21-34.	8.2	260
15	Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension. Circulation Research, 2011, 109, 867-879.	4.5	248
16	Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension. Circulation, 2005, 112, 423-431.	1.6	237
17	Ventilatory predictors of pulmonary hypoplasia in congenital diaphragmatic hernia, confirmed by morphologic assessment. Journal of Pediatrics, 1987, 111, 423-431.	1.8	234
18	Pulmonary arterial remodeling induced by a Th2 immune response. Journal of Experimental Medicine, 2008, 205, 361-372.	8.5	234

#	Article	IF	Citations
19	Disruption of PPARÎ³/Î²-cateninâ€“mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. Journal of Clinical Investigation, 2011, 121, 3735-3746.	8.2	217
20	Pathobiology of Pulmonary Hypertension. Annual Review of Pathology: Mechanisms of Disease, 2007, 2, 369-399.	22.4	210
21	Blocking Macrophage Leukotriene B ₄ Prevents Endothelial Injury and Reverses Pulmonary Hypertension. Science Translational Medicine, 2013, 5, 200ra117.	12.4	203
22	Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wntâ€“Î²-catenin and Wntâ€“RhoAâ€“Rac1 pathways. Journal of Cell Biology, 2009, 184, 83-99.	5.2	194
23	Autophagic Protein LC3B Confers Resistance against Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 649-658.	5.6	186
24	In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation, 2016, 133, 1783-1794.	1.6	183
25	BMPR2 Preserves Mitochondrial Function and DNA during Reoxygenation to Promote Endothelial Cell Survival and Reverse Pulmonary Hypertension. Cell Metabolism, 2015, 21, 596-608.	16.2	167
26	Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers. Cell Stem Cell, 2017, 20, 490-504.e5.	11.1	163
27	Overexpression of the Serine Elastase Inhibitor Elafin Protects Transgenic Mice From Hypoxic Pulmonary Hypertension. Circulation, 2002, 105, 516-521.	1.6	162
28	Tenascin-C Is Induced With Progressive Pulmonary Vascular Disease in Rats and Is Functionally Related to Increased Smooth Muscle Cell Proliferation. Circulation Research, 1996, 79, 1131-1142.	4.5	153
29	Fibronectin, hyaluronan, and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Developmental Biology, 1991, 143, 235-247.	2.0	147
30	Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease. Circulation Research, 2005, 97, 227-235.	4.5	147
31	Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension. Circulation Research, 2019, 124, 904-919.	4.5	141
32	Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. Journal of Experimental Medicine, 2021, 218, .	8.5	139
33	Landscape of cohesin-mediated chromatin loops in the human genome. Nature, 2020, 583, 737-743.	27.8	134
34	Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension. Circulation, 2008, 118, 1486-1495.	1.6	133
35	S100A4/Mts1 Produces Murine Pulmonary Artery Changes Resembling Plexogenic Arteriopathy and Is Increased in Human Plexogenic Arteriopathy. American Journal of Pathology, 2004, 164, 253-262.	3.8	132
36	Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix-bound basic fibroblast growth factor. Journal of Cellular Physiology, 1996, 166, 495-505.	4.1	129

#	Article	IF	Citations
37	Elafin Reverses Pulmonary Hypertension via Caveolin-1â€“Dependent Bone Morphogenetic Protein Signaling. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1273-1286.	5.6	125
38	Regression of Hypertrophied Rat Pulmonary Arteries in Organ Culture Is Associated With Suppression of Proteolytic Activity, Inhibition of Tenascin-C, and Smooth Muscle Cell Apoptosis. Circulation Research, 1999, 84, 1223-1233.	4.5	123
39	Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. Journal of Experimental Medicine, 2014, 211, 263-280.	8.5	123
40	Increased Pulmonary Artery Elastolytic Activity in Adult Rats with Monocrotaline-induced Progressive Hypertensive Pulmonary Vascular Disease Compared with Infant Rats with Nonprogressive Disease. The American Review of Respiratory Disease, 1992, 146, 213-223.	2.9	116
41	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	5.6	113
42	Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectinâ€“dependent neointimal formation. Nature Medicine, 1999, 5, 176-182.	30.7	101
43	Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced â€œsheddingâ€•of the 67-kDa cell surface elastin binding protein. Experimental Cell Research, 1992, 203, 344-353.	2.6	99
44	Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circulation Research, 2018, 122, 1689-1702.	4.5	97
45	Developmental expression of LC3Î± and Î²: Absence of fibronectin or autophagy phenotype in LC3Î² knockout mice. Developmental Dynamics, 2008, 237, 187-195.	1.8	93
46	Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome. Cell Stem Cell, 2020, 27, 574-589.e8.	11.1	89
47	Increased Fibulin-5 and Elastin in S100A4/Mts1 Mice With Pulmonary Hypertension. Circulation Research, 2005, 97, 596-604.	4.5	87
48	Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respiratory Research, 2011, 12, 159.	3.6	84
49	Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions. American Journal of Pathology, 2011, 179, 1560-1572.	3.8	82
50	S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phosphoâ€“Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research, 2009, 105, 639-647.	4.5	80
51	Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1â€“Mediated Metabolic and Epigenetic Changes. Circulation Research, 2019, 124, 211-224.	4.5	78
52	Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight, 2017, 2, e90427.	5.0	74
53	Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Science Translational Medicine, 2020, 12, .	12.4	74
54	Nuclear Factor-Î²B Activation in Neonatal Mouse Lung Protects against Lipopolysaccharide-induced Inflammation. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 805-815.	5.6	73

#	Article	IF	Citations
55	Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	72
56	Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 930-941.	5.6	72
57	A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nature Medicine, 1998, 4, 1383-1391.	30.7	70
58	Hyperoxia-Induced Pulmonary Vascular and Lung Abnormalities in Young Rats and Potential for Recovery. Pediatric Research, 1985, 19, 1059-1067.	2.3	66
59	RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 356-366.	5.6	66
60	BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. Journal of Cell Biology, 2011, 192, 171-188.	5.2	64
61	Leukotriene B ₄ Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension. Hypertension, 2015, 66, 1227-1239.	2.7	62
62	Î±1-Proteinase Inhibitor Therapy for the Prevention of Chronic Lung Disease of Prematurity: A Randomized, Controlled Trial. Pediatrics, 1998, 101, 89-94.	2.1	61
63	The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. Frontiers in Medicine, 2018, 5, 217.	2.6	61
64	Î±1-Antitrypsin Protects Neonatal Rats from Pulmonary Vascular and Parenchymal Effects of Oxygen Toxicity. Pediatric Research, 1994, 36, 763-770.	2.3	60
65	Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension. Nature Communications, 2020, 11, 1673.	12.8	60
66	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	5.6	59
67	Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 279-289.	0.8	58
68	SM22Î±-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development (Cambridge), 2008, 135, 2981-2991.	2.5	58
69	Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. Science Translational Medicine, 2020, 12, .	12.4	56
70	PPARÎ³ and the Pathobiology of Pulmonary Arterial Hypertension. Advances in Experimental Medicine and Biology, 2010, 661, 447-458.	1.6	56
71	Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Circulation, 2019, 140, 1409-1425.	1.6	54
72	PPARÎ³ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis. Cell Reports, 2019, 26, 1333-1343.e7.	6.4	54

#	Article	IF	Citations
73	Pulmonary Toxicity of Monocrotaline Differs at Critical Periods of Lung Development. Pediatric Research, 1985, 19, 731-737.	2.3	51
74	Functional Interplay between Interleukin-1 Receptor and Elastin Binding Protein Regulates Fibronectin Production in Coronary Artery Smooth Muscle Cells. Experimental Cell Research, 1996, 225, 122-131.	2.6	51
75	Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMPâ€mediated suppression of ERK phosphorylation and AML1B nuclear partitioning. FASEB Journal, 2000, 14, 805-814.	0.5	50
76	Reciprocal induction of tumor necrosis factorâ€Î± and interleukinâ€Î² activity mediates fibronectin synthesis in coronary artery smooth muscle cells. Journal of Cellular Physiology, 1995, 163, 19-29.	4.1	45
77	Repair of Congenital Heart Disease with Associated Pulmonary Hypertension in Children: What are the Minimal Investigative Procedures? Consensus Statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2014, 4, 330-341.	1.7	44
78	Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. Circulation, 2017, 136, 1920-1935.	1.6	44
79	Smooth Muscle Protein 22Î±â€“Mediated Patchy Deletion of Bmpr1a Impairs Cardiac Contractility but Protects Against Pulmonary Vascular Remodeling. Circulation Research, 2008, 102, 380-388.	4.5	43
80	Emerging therapies for the treatment of pulmonary hypertension. Pediatric Critical Care Medicine, 2010, 11, S85-S90.	0.5	43
81	Serum-Induced vascular smooth muscle cell elastolytic activity through tyrosine kinase intracellular signalling. Journal of Cellular Physiology, 1994, 160, 121-131.	4.1	41
82	Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug Discovery Today, 2014, 19, 1270-1276.	6.4	41
83	Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-Î² in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1559-1569.	2.4	41
84	PPARÎ³-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension. Circulation Research, 2021, 128, 401-418.	4.5	41
85	Anticipated Classes of New Medications and Molecular Targets for Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 226-244.	1.7	40
86	Reactivation of Î³HV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L276-L289.	2.9	38
87	Evolution of hemodynamic forces in the pulmonary tree with progressively worsening pulmonary arterial hypertension in pediatric patients. Biomechanics and Modeling in Mechanobiology, 2019, 18, 779-796.	2.8	38
88	Frataxin deficiency promotes endothelial senescence in pulmonary hypertension. Journal of Clinical Investigation, 2021, 131, .	8.2	38
89	Lung biopsy with frozen section as a diagnostic aid in patients with congenital heart defects. American Journal of Cardiology, 1981, 47, 77-84.	1.6	36
90	Enhanced Caspase Activity Contributes to Aortic Wall Remodeling and Early Aneurysm Development in a Murine Model of Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 146-154.	2.4	35

#	Article	IF	Citations
91	Micro <scp>RNA</scp> â€483 amelioration of experimental pulmonary hypertension. EMBO Molecular Medicine, 2020, 12, e11303.	6.9	35
92	Microtubule Involvement in Translational Regulation of Fibronectin Expression by Light Chain 3 of Microtubule-Associated Protein 1 in Vascular Smooth Muscle Cells. Circulation Research, 1998, 83, 481-489.	4.5	34
93	Loss of Adenomatous Poliposis Coli-Î±3 Integrin Interaction Promotes Endothelial Apoptosis in Mice and Humans. Circulation Research, 2012, 111, 1551-1564.	4.5	34
94	ALDH1A3 Coordinates Metabolism With Gene Regulation in Pulmonary Arterial Hypertension. Circulation, 2021, 143, 2074-2090.	1.6	34
95	Oxygen-Related Prostaglandin Synthesis in Ductus Arteriosus and Other Vascular Cells. Pediatric Research, 1989, 26, 330-335.	2.3	33
96	Endothelial and serum factors which include apolipoprotein A1 tether elastin to smooth muscle cells inducing serine elastase activity via tyrosine kinase-mediated transcription and translation. Journal of Cellular Physiology, 1998, 174, 78-89.	4.1	33
97	Caspases from apoptotic myocytes degrade extracellular matrix: a novel remodeling paradigm. FASEB Journal, 2005, 19, 1848-1850.	0.5	33
98	Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. Circulation, 2020, 142, 1605-1608.	1.6	33
99	Loss of PPARÎ³ in endothelial cells leads to impaired angiogenesis. Journal of Cell Science, 2016, 129, 693-705.	2.0	32
100	AML1-like Transcription Factor Induces Serine Elastase Activity in Ovine Pulmonary Artery Smooth Muscle Cells. Circulation Research, 1998, 83, 252-263.	4.5	28
101	EVE and beyond, retro and prospective insights. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L5-L12.	2.9	28
102	Lung matrix and vascular remodeling in mechanically ventilated elastin haploinsufficient newborn mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L464-L478.	2.9	26
103	Lymphocyte transendothelial migration toward smooth muscle cells in interleukin-1 ?-stimulated co-cultures is related to fibronectin interactions with ?4?1 and ?5?1 integrins. Journal of Cellular Physiology, 1995, 164, 620-633.	4.1	24
104	Nitric oxide mediates LCâ€3â€dependent regulation of fibronectin in ductus arteriosus intimal cushion formation. FASEB Journal, 1999, 13, 1423-1434.	0.5	24
105	Point:Counterpoint: Chronic hypoxia-induced pulmonary hypertension does/does not lead to loss of pulmonary vasculature. Journal of Applied Physiology, 2007, 103, 1449-1451.	2.5	24
106	Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancerâ€like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulmonary Circulation, 2019, 9, 1-15.	1.7	23
107	ICAM-1 and VCAM-1 expression in accelerated cardiac allograft arteriopathy and myocardial rejection are influenced differently by cyclosporine a and tumour necrosis factor-Î± blockade. Journal of Pathology, 1995, 176, 175-182.	4.5	22
108	Elafin Treatment Rescues EGFR-Klf4 Signaling and Lung Cell Survival in Ventilated Newborn Mice. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 623-634.	2.9	21

#	Article	IF	Citations
109	Role of endothelial cells in pulmonary fibrosis via SREBP2 activation. JCI Insight, 2021, 6, .	5.0	21
110	Inflammatory Basis of Pulmonary Arterial Hypertension. Anesthesiology, 2019, 131, 898-907.	2.5	20
111	Long-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model. Physiological Reports, 2017, 5, e13257.	1.7	18
112	Elastase and cell matrix interactions in the pathobiology of vascular disease. Pediatrics International, 1995, 37, 657-666.	0.5	17
113	iPSCâ€"endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension. Science Translational Medicine, 2021, 13, .	12.4	17
114	Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Chest, 2021, 160, 1442-1458.	0.8	17
115	Cellular and Molecular Pathobiology of Pulmonary Hypertension Conference Summary. Chest, 2005, 128, 642S-646S.	0.8	16
116	Right ventricular stroke work correlates with outcomes in pediatric pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-9.	1.7	16
117	Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. European Respiratory Journal, 2021, 57, 2002428.	6.7	16
118	LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. Journal of Cell Science, 2009, 122, 1441-1451.	2.0	13
119	A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L502-L516.	2.9	13
120	Monocyte released HERV-K dUTPase engages TLR4 and MCAM causing endothelial mesenchymal transition. JCI Insight, 2021, 6, .	5.0	13
121	Pathobiology of pulmonary hypertension: Impact on clinical management. Pediatric Cardiac Surgery Annual, 2000, 3, 63-81.	1.2	12
122	Tumor Necrosis Factor-Î± Induces Fibronectin Synthesis in Coronary Artery Smooth Muscle Cells by a Nitric Oxideâ€"Dependent Posttranscriptional Mechanism. Circulation Research, 2001, 89, 26-32.	4.5	12
123	Relation of Cytokine Profile to Clinical and Hemodynamic Features in Young Patients With Congenital Heart Disease and Pulmonary Hypertension. American Journal of Cardiology, 2017, 119, 119-125.	1.6	11
124	Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia. Biomechanics and Modeling in Mechanobiology, 2013, 12, 33-42.	2.8	10
125	NETs Activate Pulmonary Arterial Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2035-2037.	2.4	10
126	Genomic integrity of human induced pluripotent stem cells across nine studies in the NHLBI NextGen program. Stem Cell Research, 2020, 46, 101803.	0.7	10

#	Article	IF	Citations
127	Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1019-1034.	5.6	10
128	Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments. Pulmonary Circulation, 2019, 9, 1-13.	1.7	9
129	Computational simulation-derived hemodynamic and biomechanical properties of the pulmonary arterial tree early in the course of ventricular septal defects. Biomechanics and Modeling in Mechanobiology, 2021, 20, 2471-2489.	2.8	8
130	Image-based scaling laws for somatic growth and pulmonary artery morphometry from infancy to adulthood. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H432-H442.	3.2	7
131	Gene Transfer of the Serine Elastase Inhibitor Elafin Protects Against Vein Graft Degeneration. Circulation, 2000, 102, .	1.6	7
132	Tissue-Specific and Developmental Regulation of Transforming Growth Factor-Î²1 Expression in Fetal Lamb Ductus Arteriosus Endothelial Cells. Pediatric Research, 1998, 44, 865-872.	2.3	7
133	Pulmonary Circulation. , 2010, , 117-141.		5
134	Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics. Mediators of Inflammation, 2016, 2016, 1-9.	3.0	5
135	Balloon occlusion pulmonary wedge angiography and lung biopsy assessment in the child with a congenital cardiac defect. Cardiology in the Young, 2009, 19, 13-15.	0.8	3
136	Combining Induced Pluripotent Stem Cell with Next Generation Sequencing Technology to Gain New Insights into Pathobiology and Treatment of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 153-155.	1.7	3
137	KMT2D-NOTCH Mediates Coronary Abnormalities in Hypoplastic Left Heart Syndrome. Circulation Research, 2022, 131, 280-282.	4.5	3
138	VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy. Seminars in Immunopathology, 1995, 16, 443-65.	4.0	2
139	In memory of Dr. Stella Van Praagh. Cardiovascular Pathology, 2006, 15, 359-360.	1.6	0
140	Rescuing the BMPR2 Pathway: How and Where Can We Intervene?. Advances in Pulmonary Hypertension, 2012, 11, 124-127.	0.1	0
141	Pathology, Pathobiology and Pathophysiology of Pulmonary Arterial Hypertension. , 2014, , 2081-2101.		0